Cambrex Announces Investment at Karlskoga Site

East Rutherford, NJ - Cambrex Corporation (NYSE: CBM, "Cambrex") has initiated detailed engineering for an expansion at its Karlskoga, Sweden site to increase production capacity for small-molecule active pharmaceutical ingredients (APIs). This project, scheduled to start in July 2007 for completion by early 2009, will add a flexible, mid-sized cGMP manufacturing plant that will complement existing large-scale and small-scale facilities. This expansion represents a key component of Cambrex's strategic effort to enhance its position in high-value, fast-growing niche markets through capital investments and internal development programs at its world-class manufacturing sites.

“With our robust custom development pipeline at Cambrex Karlskoga, we intend to use this facility to manufacture APIs and advanced intermediates to support our customers' growing portfolio of late-stage clinical projects as well as subsequent commercial needs,” said Steven M. Klosk, Executive Vice President and Chief Operating Officer of Cambrex Corporation.

“We anticipate a substantial increase in demand over the next few years and look forward to expanding our operations to meet the future needs of our customers,” said Ulf Nordzell, Site Manager of Cambrex Karlskoga.

Cambrex Karlskoga currently produces over twenty commercial pharmaceutical products and completed over thirty clinical phase projects in 2006, utilizing its kilo lab, multiple pilot plants and large-scale cGMP facilities.